AR089837A1 - Derivado de paroxetina - Google Patents

Derivado de paroxetina

Info

Publication number
AR089837A1
AR089837A1 ARP130100262A ARP130100262A AR089837A1 AR 089837 A1 AR089837 A1 AR 089837A1 AR P130100262 A ARP130100262 A AR P130100262A AR P130100262 A ARP130100262 A AR P130100262A AR 089837 A1 AR089837 A1 AR 089837A1
Authority
AR
Argentina
Prior art keywords
paroxetine
derivative
paroxetine derivative
compound
retains
Prior art date
Application number
ARP130100262A
Other languages
English (en)
Spanish (es)
Inventor
Tanaka Keigo
Nishioka Tomoki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR089837A1 publication Critical patent/AR089837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP130100262A 2012-01-31 2013-01-29 Derivado de paroxetina AR089837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261592896P 2012-01-31 2012-01-31

Publications (1)

Publication Number Publication Date
AR089837A1 true AR089837A1 (es) 2014-09-17

Family

ID=48870749

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100262A AR089837A1 (es) 2012-01-31 2013-01-29 Derivado de paroxetina

Country Status (16)

Country Link
US (1) US8933100B2 (enExample)
EP (1) EP2810942B1 (enExample)
JP (1) JP6055784B2 (enExample)
KR (1) KR101950057B1 (enExample)
CN (1) CN104039777B (enExample)
AR (1) AR089837A1 (enExample)
AU (1) AU2013216123B2 (enExample)
BR (1) BR112014016197A8 (enExample)
CA (1) CA2861479C (enExample)
ES (1) ES2576082T3 (enExample)
IL (1) IL233327A (enExample)
IN (1) IN2014CN04922A (enExample)
MX (1) MX355654B (enExample)
RU (1) RU2616610C2 (enExample)
TW (1) TW201334783A (enExample)
WO (1) WO2013115163A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43313B1 (fr) * 2015-09-02 2022-06-30 Trevena Inc Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
JP2002503248A (ja) 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ 4−フェニルピペリジン化合物
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Also Published As

Publication number Publication date
IL233327A (en) 2016-03-31
KR101950057B1 (ko) 2019-02-19
CA2861479C (en) 2017-10-10
IL233327A0 (en) 2014-08-31
JP6055784B2 (ja) 2016-12-27
CN104039777B (zh) 2016-03-02
EP2810942B1 (en) 2016-03-30
CA2861479A1 (en) 2013-08-08
EP2810942A4 (en) 2015-07-01
CN104039777A (zh) 2014-09-10
ES2576082T3 (es) 2016-07-05
TW201334783A (zh) 2013-09-01
RU2014126321A (ru) 2016-03-20
AU2013216123B2 (en) 2016-10-20
RU2616610C2 (ru) 2017-04-18
US8933100B2 (en) 2015-01-13
EP2810942A1 (en) 2014-12-10
US20130197033A1 (en) 2013-08-01
MX355654B (es) 2018-04-26
JPWO2013115163A1 (ja) 2015-05-11
KR20140117454A (ko) 2014-10-07
IN2014CN04922A (enExample) 2015-09-18
MX2014007620A (es) 2014-09-15
WO2013115163A1 (ja) 2013-08-08
BR112014016197A8 (pt) 2017-07-04
AU2013216123A1 (en) 2014-07-17
BR112014016197A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
PE20151654A1 (es) Inhibidores de cdc7
JO3387B1 (ar) مشتقات بيتولين
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
CR20140134A (es) Composiciones farmacéuticas
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
AR095097A1 (es) Compuestos de fenoxietoxi
BR112015026967A2 (pt) compostos fenoxietil di-hidro-1h-isoquinolina
CO7141429A2 (es) Nuevos compuestos de pirazol
UY35209A (es) Compuestos tricíclicos
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MY185971A (en) Pyranodipyridine compound
MX373646B (es) Halogeno-pirazoles como inhibidores de trombina.
MX2018002018A (es) Derivado de urea y uso del mismo.
IN2014CN04922A (enExample)

Legal Events

Date Code Title Description
FB Suspension of granting procedure